Evidence map›Paper›PMID 31991327›Full record

ArticleDrug and alcohol dependence2020

Effects of Interim Buprenorphine Treatment for opioid use disorder among emerging adults.

Kelly R Peck, Taylor A Ochalek, Gary J Badger, Stacey C Sigmon

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Kelly R PeckVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect Street, Burlington, VT 05401, United States. Electronic address: Kelly.Peck@uvm.edu.
Taylor A OchalekVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect Street, Burlington, VT 05401, United States.
Gary J BadgerUniversity of Vermont, Department of Biostatistics, 27 Hills Building, 105 Carrigan Drive, Burlington, VT 05405, United States.
Stacey C SigmonVermont Center on Behavior and Health, University of Vermont, 1 S. Prospect Street, Burlington, VT 05401, United States.
University of Vermont · US

Funding

Vermont Center on Behavior and HealthP20GM103644 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2013 to 2022
$21.3M
Interim Buprenorphine Treatment to bridge waitlist delays: Stage II evaluationR01DA042790 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2017 to 2021
$3.0M
Interim Treatment: Leveraging buprenophine + technology to bridge waitlist delaysR34DA037385 · NIDA · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI SIGMON, STACEY C · 2014 to 2015
$652k
NIDA NIH HHS R01 DA042790NIDA NIH HHS R34 DA037385NIGMS NIH HHS P20 GM103644
6 · The paper itself

Abstract

objectiveAlthough opioid maintenance is a first-line approach for treating opioid use disorder (OUD), suboptimal treatment outcomes have been reported among emerging adults (EAs; 18-25 years of age). In this secondary analysis, we compared treatment outcomes between EAs and older adults (OAs; ≥ 26 years of age) receiving low-barrier, technology-assisted Interim Buprenorphine Treatment (IBT) during waitlist delays to comprehensive opioid maintenance treatment.

methodParticipants were 35 individuals with OUD who received IBT consisting of 12-weeks of buprenorphine maintenance with bi-monthly clinic visits and technology-assisted monitoring. At monthly follow-up assessments, participants completed staff-observed urinalysis, the Beck Anxiety Inventory (BAI), Beck Depression Inventory (BDI-II), and Addiction Severity Index (ASI).

resultsAt study intake, EAs (n = 10) reported greater past-year intravenous drug use and greater employment, legal, and psychiatric severity (p's < .05) compared to OAs (n = 25). Despite these initial differences, there were no significant differences in the percentages of urine specimens testing negative for illicit opioids between EA and OA participants at Study Week 4 (90 % vs. 88 %, p = .99), Week 8 (80 % vs. 76 %, p = .99) or Week 12 (60 % vs. 68 %, p = .71). Relative to their older peers, EAs also demonstrated significantly greater improvements on the BAI, BDI-II, and ASI Employment and Legal subscales (p's < .05).

conclusionsDespite presenting with greater past-year intravenous drug use and psychosocial severity relative to OAs, EAs responded favorably to the IBT intervention.

Indexed as

Age FactorsAdolescentAdultBuprenorphineCounselingFemaleHumansMaleNarcotic AntagonistsOpiate Substitution TreatmentOpioid-Related DisordersPsychiatric Status Rating ScalesSubstance Abuse, IntravenousTreatment OutcomeWaiting ListsYoung AdultBuprenorphineNarcotic AntagonistsBuprenorphineEmerging adultsInterim treatmentOpioid use disorder

Identifiers

PMID31991327
PMCPMC7108757
OpenAlexW3001923304

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.